Axa S.A. Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AXA S.A. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 80,364 shares of the biopharmaceutical company's stock after selling 6,413 shares during the quarter. AXA S.A. owned 0.07% of Regeneron Pharmaceuticals worth $57,246,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Willner & Heller LLC boosted its stake in shares of Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock worth $284,000 after acquiring an additional 15 shares during the period. OLD Second National Bank of Aurora lifted its holdings in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock worth $2,025,000 after purchasing an additional 15 shares in the last quarter. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the period. TD Private Client Wealth LLC boosted its stake in Regeneron Pharmaceuticals by 9.6% in the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after purchasing an additional 15 shares during the period. Finally, Manchester Capital Management LLC grew its holdings in Regeneron Pharmaceuticals by 12.6% during the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock valued at $115,000 after buying an additional 18 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 0.4 %

Shares of REGN stock traded up $2.18 on Wednesday, reaching $560.70. 1,140,439 shares of the company's stock were exchanged, compared to its average volume of 752,727. The company's fifty day simple moving average is $621.54 and its 200 day simple moving average is $703.65. Regeneron Pharmaceuticals, Inc. has a 52 week low of $525.99 and a 52 week high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $61.30 billion, a PE ratio of 14.65, a P/E/G ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $9.55 earnings per share. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on REGN shares. StockNews.com lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Bernstein Bank decreased their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Guggenheim cut their price target on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Finally, Sanford C. Bernstein reduced their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $892.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.